The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

PolyPid announces collaboration with ImmunoGenesis in solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

PolyPid Ltd. announced a new research and development collaboration with ImmunoGenesis Inc. The collaboration focuses on the development of novel formulations utilizing PolyPid’s experience with its proprietary PLEX Technology and ImmunoGenesis’ potent STimulator of INterferon Genes agonist drug candidate to potentially enhance treatment for solid tumors.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

CPRIT awards more than $93M for cancer research and prevention

On May 21, the governing body of the Cancer Prevention and Research Institute of Texas approved 61 grants totaling more than $93 million. The grants support cancer research and prevention projects across the entire spectrum of CPRIT’s mission, including CPRIT Scholar recruitment grants, a wide array of evidence-based prevention programs, and funding for early-stage companies developing promising new treatments for cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account